Tag Archives: IFM 2009

Therapy for multiple myeloma patients TGA approved

Multiple Myeloma

A novel triplet therapy for newly diagnosed multiple myeloma (NDMM) patients is now Therapeutic Goods Administration (TGA) approved. Revlimid (lenalidomide), in combination with bortezomib and dexamethasone (RVd), is now indicated for the treatment of patients with previously untreated multiple myeloma. The medication is an immunomodulating agent that inhibits the proliferation …

Read More »